Clinical evaluation of large language model recommendations in melanoma: comparison with multidisciplinary tumor board decisions in a real-world cohort - Takeaways - MDSpire

Clinical evaluation of large language model recommendations in melanoma: comparison with multidisciplinary tumor board decisions in a real-world cohort

  • By

  • Belma Babic

  • Sefika Umihanic

  • Hedim Osmanovic

  • Nejra Selak

  • Erna Sehic-Kozica

  • Lejla Moranjkic

  • Inga Marijanovic

  • Marija Karaga

  • Amina Jalovcic Suljevic

  • Sekib Umihanic

  • Fadil Umihanic

  • Arzumana Ozegovic-Orucevic

  • June 29, 2026

  • 0 min

Share

  • 1

    The study evaluated four large language models (LLMs) for melanoma treatment recommendations against a multidisciplinary tumor board's decisions.

  • 2

    151 patients with newly diagnosed cutaneous melanoma were included in the retrospective study conducted at a single center in Bosnia and Herzegovina.

  • 3

    ChatGPT-5 Thinking demonstrated the strongest performance among the LLMs, followed by ChatGPT-4o, while Gemini 2.5 Pro and DeepSeek-V3.2 were rated lower.

  • 4

    Statistically significant differences in performance between LLMs were observed across all evaluated domains, particularly in complex treatment scenarios.

  • 5

    The study suggests that while LLMs may support melanoma MDT practice, they should not replace independent treatment decisions without further research.

Original Source(s)

Clinical evaluation of large language model recommendations in melanoma: comparison with multidisciplinary tumor board decisions in a real-world cohort

  • by Belma Babic, Sefika Umihanic, Hedim Osmanovic, Nejra Selak, Erna Sehic-Kozica, Lejla Moranjkic, Inga Marijanovic, Marija Karaga, Amina Jalovcic Suljevic, Sekib Umihanic, Fadil Umihanic, Arzumana Ozegovic-Orucevic

  • June 29, 2026

Related Content

Mixed adenoneuroendocrine carcinoma of the gallbladder: a case report and literature review

Non-gestational choriocarcinoma presenting as cervical lymphadenopathy in a male patient: a case report

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min